GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech - GSK ( NYSE:GSK ) , BioNTech ( NASDAQ:BNTX )
GSK Plc GSK shelved on Wednesday its herpes simplex virus ( HSV ) vaccine development program. The recombinant protein vaccine, dubbed GSK3943104, did not meet the study's primary efficacy objective. GSK added that the vaccine candidate will not progress to phase three studies.
| Ticker |
Sentiment |
Impact |
|
MRNA
|
Neutral
|
27 %
|
|
GSK
|
Neutral
|
69 %
|
|
PFE
|
Neutral
|
27 %
|
|
BNTX
|
Neutral
|
27 %
|
